Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


November 27, 2001 27 November, 2001

Pheromone Sciences Corp. On Track and Moving Forward


Toronto, Ontario (November 27, 2001) -- Dr. William Cochrane, Chairman of the Board and Mr. Chris Neuman, President & CEO of Pheromone Sciences Corp (CDNX:PHS), today stated that there are no corporate developments that would account for the recent change in the company's share price. They further stated that the Company continues to achieve its planned milestones with timelines remaining intact to deliver U.S. clinical trial results and a subsequent FDA submission early in 2002.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT

Lorne Woods 1(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com